Leo didn't impulsively through four million dollars at this company without understanding the massive potential of their ground-breaking laser technology. This new method of targeting previously inoperable cancers is a game changer as is the ability to effectively target areas of the brain in epileptics that were previously inoperable. And given that the B510k pathway to approval is so much faster than advancing a drug through the FDA required clinical phases prior to approval makes this software likely to be approved much faster. Bottom line - WOW.
News 
Market Data 
Discover 
